Search results
Results from the WOW.Com Content Network
On 21 November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate [COVID‑19] in people twelve years of age or older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral ...
Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by the virus SARS-CoV-1, the first identified strain of the SARS-related coronavirus. [3] The first known cases occurred in November 2002, and the syndrome caused the 2002–2004 SARS outbreak .
Scanning electron micrograph of SARS virions. Severe acute respiratory syndrome (SARS) is the disease caused by SARS-CoV-1. It causes an often severe illness and is marked initially by systemic symptoms of muscle pain, headache, and fever, followed in 2–14 days by the onset of respiratory symptoms, [13] mainly cough, dyspnea, and pneumonia.
Antiviral medications were tried in people with severe disease. [1] As of March 2020 several medications were already approved for other uses or were already in advanced testing. [43] As of April 2020 trials were investigating whether existing medications could be used effectively against the body's immune reaction to SARS-CoV-2 infection.
Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy.
SARS-related coronavirus is a member of the genus Betacoronavirus (group 2) and monotypic of the subgenus Sarbecovirus (subgroup B). [13] Sarbecoviruses, unlike embecoviruses or alphacoronaviruses, have only one papain-like proteinase (PLpro) instead of two in the open reading frame ORF1ab. [14]
[9] [10] These drugs had been further developed prior to the COVID-19 pandemic for other diseases including SARS. [11] The utility of targeting the 3CL protease in a real world setting was first demonstrated in 2018 when GC376 (a prodrug of GC373) was used to treat the previously 100% lethal cat coronavirus disease, feline infectious ...
Severe acute respiratory syndrome (SARS) Severe acute respiratory syndrome coronavirus (SARS‑CoV or SARS‑CoV‑1), a strain of severe acute respiratory syndrome–related coronavirus (SARSr‑CoV) 2002 Discovered in Foshan, China. [29] Caused the 2002–2004 SARS outbreak. Possibly originated from horseshoe bats. [30] Humans Common cold